Scarica l'app Stockscreener
0.8879
0.05%
-0.0004
Dopo l'orario di chiusura:
.87
-0.0179
-2.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SCYX Giù?
Forum
Previsione
Frazionamento azionario
Scynexis Inc Borsa (SCYX) Ultime notizie
Scynexis CEO Angulo Gonzalez buys $100k in shares By Investing.com - Investing.com Australia
Scynexis CEO Angulo Gonzalez buys $100k in shares - Investing.com
SCYNEXIS (SCYX) CEO joins private placement, adds stock and warrants - Stock Titan
SCYNEXIS, Inc. (SCYX) stock price, news, quote and history - Yahoo Finance UK
SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD TherapeuticsSlideshow (NASDAQ:SCYX) 2026-04-01 - Seeking Alpha
SCYNEXIS raises $40 million in private placement financing By Investing.com - Investing.com South Africa
SCYNEXIS acquires SCY-770 for rare kidney disease treatment By Investing.com - Investing.com South Africa
SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease - tipranks.com
SCYX Should I Buy - Intellectia AI
SCYNEXIS (SCYX) extends cash runway to 2029 with $40M PIPE and SCY-770 ADPKD deal - Stock Titan
SCYNEXIS Acquires PXL-770 (SCY-770) to Advance Innovative ADPKD Therapy with Phase 2 Trial Planned for 2026 - Minichart
SCYNEXIS Announces $40 Million Private Placement to Fund SCY-770 Development for Rare Kidney Disease - Minichart
Why did SCYX stock jump 10% in pre-market today? - MSN
SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline - tipranks.com
SCYNEXIS Raises $40 Million in Strategic Private Placement - TipRanks
SCYX to Acquire Poxel's PXL770, Targeting ADPKD Treatment Market - GuruFocus
SCYX: Acquisition of SCY-770 enables rapid entry into rare renal disease with strong clinical and commercial prospects - TradingView
Poxel Sells Kidney‑Disease Drug Candidate to Scynexis for Up to $196 Million - Contract Pharma
SCYNEXIS Acquires Novel AMPK Activator for Polycystic Kidney Disease - National Today
Scynexis (SCYX) Secures Acquisition of Innovative Kidney Disease Treatment - GuruFocus
SCYNEXIS Raises $40M in Private Placement - National Today
SCYNEXIS Inc Corporate Update Call Transcript - GuruFocus
SCYNEXIS Acquires Promising ADPKD Therapy PXL-770 - National Today
Scynexis (SCYX) Secures $40M Through Private Placement Agreement - GuruFocus
SCYNEXIS Enters $40 Million Private Placement, Completes Acquisition of PXL-770 to Treat Kidney Disease - MarketScreener
Scynexis In Spotlight After Poxel Deal, $40 Million Private Placement – SCYX Stock Climbs 2% Pre-Market - Stocktwits
Press Release: Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million - Moomoo
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million - Business Wire
Scynexis (NASDAQ: SCYX) prices $40M equity private placement with warrants - Stock Titan
Scynexis Acquires Poxel's AMPK Activator Program, Paying $8M Upfront Plus Up To $188M Milestones - TradingView
SCYNEXIS raises $40 million in private placement financing - Investing.com
SCYNEXIS acquires SCY-770 for rare kidney disease treatment - Investing.com
Scynexis (NASDAQ: SCYX) buys SCY-770 kidney drug for $8M upfront - Stock Titan
SCYNEXIS Announces $40.0 Million Private Placement - The Manila Times
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - The Manila Times
SCYX: Acquisition of SCY-770 targets ADPKD, expanding the rare disease portfolio with a novel therapy - TradingView
SCYNEXIS lands cash to fund rare disease drug work into mid-2029 - Stock Titan
Kidney disease drug with Phase 2 study due this year joins SCYNEXIS - Stock Titan
Scynexis Jumps on SCY-770 Deal — But Volume Tells a Cautious Story - Bitget
SCYNEXIS, Inc. announced that it expects to receive $40.019125 million in funding - MarketScreener
First Participants Dosed in Phase Trial of SCY-247, Building on Oral Formulation Success - Contagion Live
If You Invested $1,000 in Scynexis (SCYX) - Stock Titan
SCYNEXIS (NASDAQ:SCYX) Rating Lowered to “Hold” at Wall Street Zen - Defense World
Published on: 2026-03-22 14:13:05 - baoquankhu1.vn
EBIT per share of SCYNEXIS, Inc. – LSE:0L49 - TradingView
SCYNEXIS (SCYX) Price Target Decreased by 21.43% to 3.74 - MSN
SCYNEXIS, Inc. (SCYX) announces first participants dosed in phase 1 trial of SCY-247 antifungal therapy - MSN
SCYX SEC FilingsScynexis 10-K, 10-Q, 8-K Forms - Stock Titan
SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy - Insider Monkey
Brookline Capital cuts SCYNEXIS stock price target on valuation By Investing.com - in.investing.com
Brookline Capital cuts SCYNEXIS stock price target on valuation - Investing.com Nigeria
11 Fastest Growing Penny Stocks to Buy Right Now - Insider Monkey
Is SCYNEXIS Inc stock overvalued or fairly priced2025 EndofYear Setup & Growth Focused Investment Plans - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Scynexis Inc earnings beat by $0.12, revenue topped estimates - Investing.com Nigeria
Scynexis Q4 2025 Earnings: Profit of $12.3M, Full-Year 2025 Revenue $20.6MNews and Statistics - IndexBox
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update - The Manila Times
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):